Bellevue Healthcare Trust PLC (LSE:BBH) said it has concentrated its holdings in recent months, but the turnover remains particularly low relative to the trust's history.
The stark valuation disconnect in markets has reaffirmed the manager Paul Major’s belief that the holdings are compelling and that the trust remains well placed to benefit from normalisation in markets.
In an interview, he highlights a core holding, Sarepta Therapeutics, as a company at the forefront of gene therapy making headway in the healthcare space.